West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Health CareHealth Care Equipment & Services
  • Price (USD)209.18
  • Today's Change3.15 / 1.53%
  • Shares traded142.79k
  • 1 Year change81.31%
  • Beta1.0822
Data delayed at least 15 minutes, as of May 29 2020 15:47 BST.
More ▼

Profile data is unavailable for this security.

About the company

West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.

  • Revenue in USD (TTM)1.89bn
  • Net income in USD260.60m
  • Incorporated1923
  • Employees8.20k
  • Location
    West Pharmaceutical Services Inc530 HERMAN O WEST DREXTON 19341-1147United StatesUSA
  • Phone+1 (610) 594-2900
  • Fax+1 (800) 345-9800
  • Websitehttps://www.westpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Henry Schein, Inc.10.05bn712.82m8.77bn19.00k12.682.9412.110.87254.854.8668.3620.881.375.168.41529,179.307.246.7512.1012.0730.6929.675.284.851.0426.110.25930.006.03-0.754967.218.50-1.48--
ABIOMED, Inc.840.88m203.01m9.77bn1.54k49.099.1843.7311.624.434.4318.3623.670.74061.779.58547,449.3017.8819.0919.9721.4382.0183.2024.1423.024.14--
DENTSPLY SIRONA Inc3.96bn83.80m10.29bn15.20k128.142.2025.542.600.36670.366717.7221.390.4753.025.79260,348.701.01-3.841.13-4.2553.9153.942.12-8.671.36--0.2367--1.086.63125.90-
Varian Medical Systems, Inc.3.33bn235.40m11.27bn10.06k48.336.0533.023.382.572.5236.2920.520.86063.493.27330,759.306.108.5810.6015.0043.2742.577.0910.950.9729--0.22160.0010.481.12-16.66-5.88-8.34--
Insulet Corporation776.65m5.12m12.08bn1.35k2,288.37197.27328.4215.560.08070.080712.390.93570.75373.269.81575,292.600.4971-3.140.564-3.6264.4461.420.6595-4.193.421.460.9384--30.9326.12252.37--71.60--
Masimo Corporation975.80m211.35m12.68bn1.60k63.5510.1253.8013.003.693.6917.0323.160.73542.997.17609,873.8015.9322.0917.7926.7667.9666.5421.6625.095.49--
Hologic, Inc.3.32bn452.80m13.51bn6.48k31.096.4815.604.061.681.6812.388.080.49823.725.76513,260.306.761.498.341.7852.7553.1113.563.701.044.970.6310.004.645.8856.59--7.21--
Steris PLC3.03bn407.61m13.81bn12.00k34.214.0532.054.564.764.7635.3940.170.57747.505.27--7.774.978.575.4443.5541.4813.459.091.9119.930.252542.748.9410.3734.0624.7220.2710.01
West Pharmaceutical Services Inc.1.89bn260.60m15.16bn8.20k59.6510.1842.798.033.453.4525.0220.250.88165.295.80230,231.7011.709.4813.7711.2033.1532.4913.2710.892.11--0.14721.647.135.3018.2513.722.438.27
Teleflex Incorporated2.61bn551.22m16.63bn14.40k30.665.4121.676.3711.6811.7055.3966.200.40292.426.39181,418.108.505.519.156.1856.6755.1021.1012.852.387.860.43821.636.007.12135.1919.408.730.00
Cooper Companies Inc2.67bn448.20m16.89bn12.00k35.184.1823.116.329.009.1253.6475.830.41591.796.70222,625.006.986.608.277.4466.0663.1116.7815.050.58348.060.32260.87774.769.0930.0111.304.180.00
Align Technology, Inc.2.41bn1.89bn19.63bn14.53k10.456.889.968.1523.8523.8530.2436.220.77717.104.76165,780.3061.0618.6084.4226.4172.0874.1678.5719.471.60--0.000.0022.3925.8710.6324.8744.10--
Data as of May 29 2020. Currency figures normalised to West Pharmaceutical Services Inc's reporting currency: US Dollar USD

Institutional shareholders

45.41%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20207.54m10.25%
BlackRock Fund Advisorsas of 31 Mar 20206.20m8.43%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20205.32m7.23%
Franklin Advisers, Inc.as of 31 Mar 20204.07m5.53%
SSgA Funds Management, Inc.as of 31 Mar 20202.79m3.79%
Neuberger Berman Investment Advisers LLCas of 31 Mar 20202.15m2.92%
BAMCO, Inc.as of 31 Mar 20201.44m1.96%
WCM Investment Management LLCas of 31 Mar 20201.41m1.92%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20201.30m1.76%
Artisan Partners LPas of 31 Mar 20201.20m1.63%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.